Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121106 | PMC |
| http://dx.doi.org/10.1136/rmdopen-2022-002323 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of casirivimab/imdevimab (REGEN-COV) in pregnant individuals with COVID-19: Literature review and insights from the COVID-19 International Drug Pregnancy Registry.
Obstet Med
June 2025
Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Introduction: Casirivimab/imdevimab (CAS/IMD) comprises two monoclonal antibodies that neutralize SARS-CoV-2. Pregnant individuals were excluded from initial trials, limiting safety data.
Methods: The COVID-19 International Drug Pregnancy Registry enrolled 53 pregnant women treated with CAS/IMD, with 34 live births.
Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients.
PLoS One
April 2025
Department of Health Sciences, Università degli Studi di Milano, Milano, Italy.
Background: Anti-SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) have been shown to have clinical benefits in treating high-risk patients with mild-moderate COVID-19. SARS-CoV-2 RNA in serum (RNAemia), is usually associated with severe disease and deaths. This study evaluates real-life data on the effectiveness of mAbs therapies against SARS-CoV-2 infections by different viral variants, particularly in the presence of RNAemia, focusing on clinical outcomes.
View Article and Find Full Text PDFEffectiveness of pharmacological treatments for COVID-19 due to SARS-CoV-2: a systematic literature review.
Front Pharmacol
February 2025
Health Value, Madrid, Spain.
Aim: Since the first cases of the COVID-19 pandemic, caused by the SARS-CoV-2 virus, described in 2019, numerous drugs have been proposed for the treatment of the disease. However, studies have given contradictory or inconclusive results, making it difficult to determine which treatments are truly effective. The objective was to carry out a systematic review of the literature analyzing the effectiveness (mortality, hospitalization and clinical improvement) of COVID-19 treatments initially proposed and finally authorized in the European Union.
View Article and Find Full Text PDFInnate and SARS-CoV-2 specific adaptive immune response kinetic in neutralizing monoclonal antibody successfully treated COVID-19 patients.
Int Immunopharmacol
February 2025
Unit of Pathogen Specific Immunity, Bambino Gesù Children's Hospital, IRCCS, Rome 00146 Italy. Electronic address:
The impact of anti-Spike monoclonal antibody (mAbs) treatment on the immune response of COVID19-patients is poorly explored. In particular, a comparison of the immunological influence of different therapeutic regimens has not yet been performed. Aim of the study was to compare the kinetic of innate and adaptive immune response as well as the SARS-CoV-2 specific humoral and T cell response in two groups of SARS-CoV-2-infected patients treated with two different mAbs regimens: Bamlanivimab/Etesevimab (BAM/ETE) or Casirivimab/Imdevimab (CAS/IMD).
View Article and Find Full Text PDFMonoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection.
Sci Transl Med
November 2024
Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Article Synopsis
- The study investigates how antiviral monoclonal antibodies (mAbs), particularly casirivimab and imdevimab (CAS+IMD), affect immune responses when individuals are vaccinated against SARS-CoV-2 after receiving mAb treatment.
- It was found that the presence of CAS+IMD during vaccination reduced the effectiveness of the vaccine in generating neutralizing antibodies, though other immune responses remained intact.
- This reduction in antibody production is linked to "epitope masking," but can be reversed with booster shots, and influences the immune response differently in those who had not yet begun their natural immunity when treated with mAbs.